These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 33745436)

  • 41. Regulatory structures for gene therapy medicinal products in the European Union.
    Klug B; Celis P; Carr M; Reinhardt J
    Methods Enzymol; 2012; 507():337-54. PubMed ID: 22365782
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PTML Model for Selection of Nanoparticles, Anticancer Drugs, and Vitamins in the Design of Drug-Vitamin Nanoparticle Release Systems for Cancer Cotherapy.
    Santana R; Zuluaga R; Gañán P; Arrasate S; Onieva E; Montemore MM; González-Díaz H
    Mol Pharm; 2020 Jul; 17(7):2612-2627. PubMed ID: 32459098
    [TBL] [Abstract][Full Text] [Related]  

  • 43. European Union directives and their effect on the registration and authorisation of anthroposophic and homeopathic medicines.
    Laso LR; Alfonso-Galán MT
    Med Law; 2009 Mar; 28(2):269-82. PubMed ID: 19705642
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Scientific advice by the nationally competent authority and by the EMEA on the conduct of clinical trials].
    Dejas-Eckertz P; Schäffner G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):423-8. PubMed ID: 15830253
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hurdles of environmental risk assessment procedures for advanced therapy medicinal products: comparison between the European Union and the United States.
    Iglesias-Lopez C; Obach M; Vallano A; Agustí A; Montané J
    Crit Rev Toxicol; 2019 Aug; 49(7):580-596. PubMed ID: 31846383
    [TBL] [Abstract][Full Text] [Related]  

  • 46. EU decision-making for marketing authorization of advanced therapy medicinal products: a case study.
    de Wilde S; Coppens DGM; Hoekman J; de Bruin ML; Leufkens HGM; Guchelaar HJ; Meij P
    Drug Discov Today; 2018 Jul; 23(7):1328-1333. PubMed ID: 29574211
    [TBL] [Abstract][Full Text] [Related]  

  • 47. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PTML Multi-Label Algorithms: Models, Software, and Applications.
    Ortega-Tenezaca B; Quevedo-Tumailli V; Bediaga H; Collados J; Arrasate S; Madariaga G; Munteanu CR; Cordeiro MNDS; González-Díaz H
    Curr Top Med Chem; 2020; 20(25):2326-2337. PubMed ID: 32938352
    [TBL] [Abstract][Full Text] [Related]  

  • 49. European regulations on nutraceuticals, dietary supplements and functional foods: a framework based on safety.
    Coppens P; da Silva MF; Pettman S
    Toxicology; 2006 Apr; 221(1):59-74. PubMed ID: 16469424
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evolution of European Union legislation of herbal medicinal products and its transposition to national legislation in 1965-2007: case Finland.
    Koski SM; Laitinen-Parkkonen P; Airaksinen M
    Int J Health Plann Manage; 2015; 30(3):260-75. PubMed ID: 24375722
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The certification of advanced therapy medicinal products. A quality label for product development in small and medium-sized enterprises].
    Berger A; Schüle S; Flory E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):816-21. PubMed ID: 21698534
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Introduction.
    Giulini SM; Stagnitti F
    Ann Ital Chir; 2019; 90():371-372. PubMed ID: 31815733
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents.
    Vezér B; Buzás Z; Sebeszta M; Zrubka Z
    Curr Med Res Opin; 2016 May; 32(5):829-34. PubMed ID: 26808864
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Main changes in European Clinical Trials Regulation (No 536/2014).
    Tenti E; Simonetti G; Bochicchio MT; Martinelli G
    Contemp Clin Trials Commun; 2018 Sep; 11():99-101. PubMed ID: 30003173
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Marketing authorization of veterinary medicinal products in Poland.
    Sztabińska-Koncka H; Lewicki J
    Regul Toxicol Pharmacol; 1997 Aug; 26(1 Pt 1):129-33. PubMed ID: 9339489
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The European hospital exemption clause-new option for gene therapy?
    Buchholz CJ; Sanzenbacher R; Schüle S
    Hum Gene Ther; 2012 Jan; 23(1):7-12. PubMed ID: 22247961
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Artificial Intelligence and Machine Learning in Computational Nanotoxicology: Unlocking and Empowering Nanomedicine.
    Singh AV; Ansari MHD; Rosenkranz D; Maharjan RS; Kriegel FL; Gandhi K; Kanase A; Singh R; Laux P; Luch A
    Adv Healthc Mater; 2020 Sep; 9(17):e1901862. PubMed ID: 32627972
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Procedure for the marketing authorization of an antibacterial agent].
    López Navas A; García-Escribano Ráez N; Flores Juberías Á; Suárez Gea ML
    Enferm Infecc Microbiol Clin; 2014 Oct; 32(8):529-32. PubMed ID: 25124488
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Regulation of immunological veterinary medicinal products in the European Union.
    Brunko P
    Rev Sci Tech; 1995 Dec; 14(4):1133-41. PubMed ID: 8639951
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Excipients: regulatory aspects].
    Artiges A
    Therapie; 1999; 54(1):15-9. PubMed ID: 10216417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.